- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00764998
Influenza Vaccine in HIV
A Controlled Trial to Assess the Immunogenicity and Efficacy of Three Vaccine Dosing Strategies in HIV Infected Adults
The purposes of this research study are:
- to see if there is a difference in the quantity of protective influenza antibodies produced by different doses of the Fluviral vaccine
- to see if these different vaccine dosing schedules reduce flu-like illness and/or reduce laboratory documented influenza in HIV Infected adults.
Aperçu de l'étude
Description détaillée
Immune compromised individuals are at risk for infection with influenza and more likely to manifest more severe symptoms of influenza disease. Furthermore, they are influenza vaccine hyporesponsive in comparison to healthy, adult immune competent individuals. One population of immune compromised Canadians at risk for severe influenza disease is those living with HIV infection. At least 56,000 Canadians are HIV infected [1]. This population is at risk for more severe influenza illness. Influenza viral replication and shedding is prolonged and the duration of influenza symptomatology is longer in those with HIV [2, 3]. Furthermore, influenza-related mortality rates in HIV infected individuals are increased [4]. The HIV population is known to be hyporesponsive to vaccinations, including influenza. The efficacy of influenza vaccines is compromised, in part, by reduced antibody responses observed in HIV infected individuals [5]. Nevertheless, influenza vaccination is recommended for HIV-infected individuals [6, 7]. The Centers of Disease Control guidelines state: "Influenza can result in serious illness and because vaccination with inactivated influenza vaccine might result in the production of protective antibody titers, vaccination might benefit HIV-infected persons. Therefore, influenza vaccination is recommended". As influenza vaccination is the cornerstone of public health interventions intended to protect the population against influenza, vaccine hyporesponsiveness in immune compromised populations represents a significant concern. Given the risk of influenza exposure in general as well as concerns related to poor vaccine efficacy and more severe influenza disease in immune compromised populations such as those living with HIV, strategies to improve vaccine efficacy are required.
Therefore a total of 5 conditions provide justification for a trial to be conducted at this time:
- current standard treatment with influenza vaccine is less efficacious when used in particular subgroups of immune compromised individuals, such as those diagnosed with HIV
- there exists a significant burden of influenza infection in HIV patients that must be addressed in terms of identifying an effective treatment strategy
- past randomized trials of influenza vaccination in HIV patients are of limited comparability to today's relevant base of patients, and alternative vaccination strategies require assessment
- efficacy of booster doses of influenza vaccine in HIV patients remains in question as a consequence of methodologic shortcomings in terms of both design aspects and outcomes measured of past studies
- there is a paucity of published evidence assessing the efficacy of an increased, double-dose of influenza vaccine in this patient population.
References
- Boulos, D., et al., Estimates of HIV prevalence and incidence in Canada, 2005. Can Commun Dis Rep, 2006. 32(15): p. 165-74.
- Safrin, S., J.D. Rush, and J. Mills, Influenza in patients with human immunodeficiency virus infection. Chest, 1990. 98(1): p. 33-7.
- Radwan, H.M., et al., Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis, 2000. 31(2): p. 604-6.
- Zanetti, A.R., et al., Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine, 2002. 20 Suppl 5: p. B29-32.
- Malaspina, A., et al., Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis, 2005. 191(9): p. 1442-50.
- Health Canada Progress towards Canadian target coverage rates in Influenza and Pneumococcal Immunications., in Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/01vol27/dr2710eb.htlm. Accessed 8 December 2006. 2006.
- Prevention and Control of Influenza. Recommendations of the advisory committee on immunization practice, in Centers for Disease Control and Prevention. Morbidity and Morality Weekly Report. 2006. p. Vol 55/RR-10.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Alberta
-
Calgary, Alberta, Canada, T2R 0X7
- Southern Alberta Clinic
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- BC Center for Excellence in HIV/Aids
-
Vancouver, British Columbia, Canada, V6Z 2C7
- Downtown Immunodeficiency Clinic / UBC
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- QEII HSC, Victoria General Hospital Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- McMaster University Medical Center
-
London, Ontario, Canada, N5Y 3H6
- Infectious Disease Care Program
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital, General Campus
-
Toronto, Ontario, Canada, M5G 2N2
- University Health Network
-
Toronto, Ontario, Canada, K1N 6N5
- University of Ottawa Health Services
-
Toronto, Ontario, Canada, M2N 3M5
- Sunnybrook Health Science Center
-
Windsor, Ontario, Canada, N8W 1E3
- HIV Care Program - Windsor Regional Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 2P4
- Immunodeficiency Service, Montreal Chest Institute
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 18 - < 60 years
- HIV positive
- Able to provide signed, informed consent.
Exclusion Criteria:
- Receipt or anticipated requirement of any blood product, vaccine, or immunoglobulin preparation within one month of study vaccine administration until completion of study.
- Immunosuppressive therapy including prednisone, immune modulators, subjects undergoing dialysis, autoimmune dysfunction (including rheumatoid arthritis, lupus erythematosus, multiple sclerosis)
- Alcohol consumption > 4 drinks per day (1 drink is equal to a 12-ounce can of beer, or a 5-ounce glass of wine or one cocktail with 1 1/2-ounces alcohol)
- History of cancer, with the exception of cutaneous cancers including Kaposi Sarcoma, basal cell carcinoma and non-invasive HPV-related malignancy
- Known or suspected hypersensitivity to any component of the study vaccines, including chicken eggs or egg products and thimerosol
- History of immediate hypersensitivity reaction and/or reaction resulting in neurological symptoms to a previous dose of any influenza vaccine
- Presentation with or any recent history (within 24 hours) of any febrile illness (> 38 C) or symptoms of significant local or systemic infection - such subjects will be deferred from enrollment at least until one week after the illness has resolved
- Any other condition which in the opinion of the Investigator might interfere with evaluation of the study objectives.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: placebo
|
Autres noms:
|
Comparateur actif: Fluviral
|
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Immunogenicity measured by haemagglutination inhibition (HI)
Délai: baseline, week 4, week 8 and week 20.
|
baseline, week 4, week 8 and week 20.
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Frequencies of laboratory confirmed influenza and Frequencies clinical/respiratory illness
Délai: event driven
|
event driven
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Curtis Cooper, MD, OHRI
Publications et liens utiles
Publications générales
- Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, Shafran S, Zubyk W, Singer J, Halperin S, Walmsley S; CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One. 2011 Mar 25;6(3):e17758. doi: 10.1371/journal.pone.0017758.
- Nosyk B, Sharif B, Sun H, Cooper C, Anis AH; CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus. PLoS One. 2011;6(12):e27059. doi: 10.1371/journal.pone.0027059. Epub 2011 Dec 6.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CTN237
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur VIH
-
Icahn School of Medicine at Mount SinaiIRRASRecrutementHémorragie intraventriculaire (HIV)États-Unis
-
Yale UniversityComplétéPrématurité | Nourrissons de très faible poids à la naissance | Hémorragie intraventriculaire (HIV) | Saignement dans le cerveauÉtats-Unis
Essais cliniques sur Fluviral
-
brian.wardMedTeq; MEDICAL INTERNATIONAL TECHNOLOGIES (MIT CANADA) INC.Complété
-
GlaxoSmithKlineComplété
-
GlaxoSmithKlineComplété
-
GlaxoSmithKlineID Biomedical Corporation, QuebecComplété
-
Mount Sinai Hospital, CanadaGlaxoSmithKlineComplété
-
ID Biomedical Corporation, QuebecInconnue
-
University of AlbertaComplétéVaccin contre la grippeCanada
-
Mount Sinai Hospital, CanadaGlaxoSmithKlineComplété
-
ID Biomedical Corporation, QuebecComplété